Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The present study will provide information on whether the somatostatin analog, octreotide
acetate, could have an inhibitory effect on circulating chromogranin A. The demonstration of
an antisecretory effect of somatostatin analogs could offer a rationale for a large scale
randomized study.